Hims & Hers Stock ALERT! -- Everything You Need to Know
Overall SentimentBullishStrength: 75%
Overall Thesis
Despite a 13% stock drop from an FTC lawsuit, Hims & Hers' fundamentals remain intact and the legal challenge represents a buying opportunity, as the company's disruptive healthcare model threatens traditional pharma.
Narratives
HIMSHims & Hers Health
BullishTravis argues the FTC lawsuit against Hims & Hers is a short-term headline, not a structural threat, and actually signals that the company is winning against incumbent pharma by disrupting the industry. He views the stock's 13% drop as a potential buying opportunity similar to the earlier Novo Nordisk lawsuit dip, citing the company's strong subscriber growth, transparent pricing, and small fines relative to its $2.4 billion revenue base.
Key Arguments
- Big pharma is terrified of Hims & Hers becoming the 'front door' to healthcare, as shown by the peptide hearing and now the FTC lawsuit.
- The specific FTC allegations (billing before provider visit, difficult cancellation, data sharing) are not serious issues based on his personal use of the app.
- Comparable FTC fines against other digital health companies have ranged from $1.5 million to $10 million, which would be immaterial against Hims & Hers' $2.4 billion in revenue.
- The earlier Novo Nordisk lawsuit caused a similar stock drop that turned out to be a great buying opportunity.
- Regulatory and legal pushback from incumbents is itself evidence that Hims & Hers is winning market share, similar to taxis fighting Uber.
- Hims & Hers is the biggest position in his Asymmetric Investing portfolio.
Predictions (1)
Bullin 2027
unverifiableDetails
Hedges & Caveats
- FTC lawsuit involves three substantive claims: data sharing practices, charging before provider meetings, and difficult cancellation processes
- Investigation disclosed years ago with $15 million charge-off already taken
- Short-term stock volatility expected but characterized as noise rather than structural risk
- Comparison drawn to previous Nova Nordisk lawsuit that initially caused stock to crater but proved to be buying opportunity
Analyzed with claude-sonnet-5 | Extraction v1.0.0 | Cost: $0.08